BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34556806)

  • 21. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
    Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
    Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of bone marrow mesenchymal stem cells on acute graft versus host disease and graft versus leukemia after allogeneic bone marrow transplantation].
    Hu WB; Gao QP; Chen YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):404-7. PubMed ID: 15972130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.
    Zheng CC; Zhu XY; Tang BL; Zhang XH; Zhang L; Geng LQ; Liu HL; Sun ZM
    Bone Marrow Transplant; 2017 Jan; 52(1):88-94. PubMed ID: 27376453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
    Truitt RL; Atasoylu AA
    Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
    Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
    Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
    Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
    J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
    Hattori K; Hirano T; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K
    Br J Haematol; 1999 Apr; 105(1):303-12. PubMed ID: 10233398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
    Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ
    Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
    Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
    J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
    Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
    Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation.
    Imamura M; Tsutsumi Y; Miura Y; Toubai T; Tanaka J
    Hematology; 2003 Feb; 8(1):19-26. PubMed ID: 12623423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
    Reddy P; Maeda Y; Hotary K; Liu C; Reznikov LL; Dinarello CA; Ferrara JL
    Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3921-6. PubMed ID: 15001702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects.
    Johnston HF; Xu Y; Racine JJ; Cassady K; Ni X; Wu T; Chan A; Forman S; Zeng D
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1089-103. PubMed ID: 24796279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.